


- 51 -

CLAIMS

1. A compound of the formula



5 wherein:

n is an integer of from 0 to 2;

Z is N, N(O), O, S, S(O), S(O)₂, P, P(O), P(O)₂, Si, Si(O), or Si(O)₂;

each X is independently C, C(O), N, N(O), O, S, S(O), S(O)₂, P, P(O), P(O)₂, Si, Si(O), or Si(O)₂ or is a bond; and

10 each of R₁ to R₆ is independently a bond or is selected from the group consisting of:

hydrogen;

halogen;

straight chain, cyclic, branched, substituted, heterocyclic, heteroatom substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

15 phosphoryl groups such as phosphate, thiophosphate -O-P(S)(OH)₂; phosphate esters -O-P(O)(OR)₂; thiophosphate esters -O-P(S)(OR)₂; phosphonate -O-P(O)OHR; thiophosphonate -O-P(S)OHR; substituted phosphonate -O-P(O)OR₁R₂; substituted thiophosphonate -O-P(S)OR₁R₂; -O-P(S)(OH)(SH); and cyclic phosphate;

20 other phosphorus containing compounds such as phosphoramidite

-O-P(OR)-NR₁R₂; and phosphoramidate -O-P(O)(OR)-NR₁R₂;

sulfur groups such as -O-S(O)(OH), -SH, -SR, -S(→O)-R, S(O)₂R, RO-S(O)₂⁻, -O-SO₂NH₂, -O-SO₂R₁R₂ or sulfamide -NHSO₂NH₂;

amino groups such as -NHR, -NR₁R₂, -NHAc, -NHCOR, -NH-O-COR, -


25 NHSO₃, -NHSO₂R, -N(SO₂R)₂, and/or amidino groups such as -NH-

C(=NH)NH₂ and/or ureido groups such as -NH-CO-NR₁R₂ or thiouriedo groups such as -H-C(S)-NH₂;

another unit of the structure **I**, attached through any position, where Z, X and R₁ to R₆ are as defined above; or

30 a substructure based upon a group of the following formula:

- 52 -



wherein:

Y is a bond or is selected from the group consisting of: straight chain, cyclic, branched, substituted, heterocyclic, heteroatom substituted or unsubstituted alkyl; straight chain, cyclic, branched, substituted, heterocyclic, heteroatom substituted or unsubstituted acyl; and aryl, substituted aryl, heteroaryl;

and

each of R₇ to R₁₁ is independently at least one structure according to formula I, or a structure according to formula II;

with the provisos that:

when Z is O, and X is O or a bond, then all of R₁ to R₅ are not H or CH₂OH; or

when Z is N and X is O or a bond, then all of R₁ to R₆ are not H.

2. A compound according to claim 1, wherein said compound is PG2024, PG2037, PG2046, PG2155, as hereinbefore described.

3. A compound according to claim 1, wherein said compound is any one of the compounds of Tables 1-4 of the description.

4. A pharmaceutical or veterinary composition for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection, which composition comprises at least one compound according to claim 1 together with a pharmaceutically or veterinarily acceptable carrier or diluent for said at least one compound.

5. The composition according to claim 4 which further includes a pharmaceutically or veterinarily acceptable excipient, buffer, stabiliser, isotonicising agent, preservative or antioxidant.

6. The composition according to claim 4, wherein said compound is present therein as an ester, a free acid or base, a hydrate, or a prodrug.

7. Use of a compound according to claim 1 in the manufacture of a medicament for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection.

8. The use according to claim 7, wherein said mammalian subject is a human subject.

9. A method for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection, which method comprises administering to the subject an effective amount
5 of at least one compound according to claim 1, or a composition comprising said at least one compound.

10. The method according to claim 9 wherein said mammalian subject is a human subject.

11. The method according to claim 9, wherein said disorder resulting from angiogenesis is a proliferative retinopathy or angiogenesis resulting from the growth of a solid tumour.

10 12. The method according to claim 9, wherein said disorder resulting from inflammation is rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, allograft rejection or chronic asthma.

13. The method according to claim 9, wherein said disorder resulting from coagulation and/or thrombosis is deep venous thrombosis, pulmonary embolism, thrombotic stroke,
15 peripheral arterial thrombosis, unstable angina or myocardial infarction.

14. The method according to claim 9, wherein said disorder resulting from viral infection is Herpes Simplex.